✦ LIBER ✦

Changes in serum lipid concentrations in patients with chronic hepatitis C virus positive hepatitis responsive or non-responsive to interferon therapy

✍ Scribed by SACHIKO HAMAMOTO; YASUSHI UCHIDA; TOMOKO WADA; MAKOTO MORITANI; SHUICHI SATO; NAOHARU HAMAMOTO; SHUNJI ISHIHARA; MAKOTO WATANABE; YOSHIKAZU KINOSHITA

Book ID: 108949981
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 129 KB
Volume: 20
Category: Article
ISSN: 0815-9319
DOI: 10.1111/j.1440-1746.2004.03526.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Serum hepatitis C virus (HCV)-RNA and re

Serum hepatitis C virus (HCV)-RNA and response to alpha-interferon in anti-HCV positive chronic hepatitis

✍ Dr. S. Magrin; A. Craxi; C. Fabiano; G. Fiorentino; L. Marino; P. Almasio; G. B. 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 731 KB

## Abstract Hepatitis C virus (HCV) replication was assessed before and during alpha‐interferon (IFN) treatment in 22 anti‐HCV positive patients with posttransfusion or sporadic chronic hepatitis (CH). Eleven patients were “responders” and 11 patients “non‐responders” to IFN. Thirteen anti‐HCV nega

Virological patterns of hepatitis C viru

Virological patterns of hepatitis C virus in chronic hepatitis C with biochemical sustained response to interferon therapy

✍ M S De Mitri; T Iervese; E Pisi; G Morsica; A Lazzarin 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB 👁 2 views

CORRESPONDENCE 1287 tive anions determine the potential for crystal precipi-though the location within the stone is not identified. Thus, their data would seem to confirm our findings tation within bile. Certain disease states predispose and be in conflict with the statement in their letter to supe

Hepatitis C virus genome complexity corr

Hepatitis C virus genome complexity correlates with response to interferon therapy: A study in French patients with chronic hepatitis C

✍ B Le Guen; G Squadrito; B Nalpas; P Berthelot; S Pol; C Brechot 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 216 KB 👁 2 views

Recent studies performed in Japan have suggested that hepatitis C virus (HCV) genome heterogeneity might be taken as a predictive virological parameter of response to interferon alfa (IFN-alpha) treatment. However, there is presently no information on the impact of this virological parameter in pati

Serum hepatitis C virus RNA level as a p

Serum hepatitis C virus RNA level as a predictor of subsequent response to interferon-α therapy in Japanese patients with chronic hepatitis C

✍ Etsuro Onto; Masashi Mizokami; Tatsunori Nakano; Hisahiro Terashima; Osamu Nojir 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 426 KB 👁 1 views

## Abstract Serum hepatitis C virus (HCV) RNA level has been shown to be a good predictor of subsequent response to interferon‐α (IFN) therapy in US patients in whom genotype 1a/1b are both predominant. To determine whether serum HCV RNA level is a predictor of subsequent response to IFN in Japanes

Racial differences in responses to thera

Racial differences in responses to therapy with interferon in chronic hepatitis C

✍ K. Rajender Reddy; Jay H. Hoofnagle; Myron J. Tong; William M. Lee; Paul Pockros 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 185 KB 👁 2 views

The likelihood of a sustained response to a course of interferon in patients with chronic hepatitis C correlates with several clinical and viral factors, including age, viral genotype and initial levels of hepatitis C virus (HCV) RNA in serum. The role of race and ethnicity has not been assessed. We

Genotypes and titers of hepatitis C viru

Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C

✍ Kunihiko Hino; Shigehiko Sainokami; Kazumi Shimoda; Shiro Iino; Yu Wang; Hiroaki 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 708 KB

## Abstract Interferon induces remission in about 50% of patients with chronic hepatitis C, but it is difficult to predict which patients will respond. Host and viral factors were evaluated for correlation with response to interferon in patients with chronic hepatitis C. Recombinant interferon alph